Of course, since Rodia prevents cognitive deterioration. Thirteen published clinical trials that examined 4054 patients in total, evaluated the use of alphoscerate choline in various forms of
degenerative dementia disorders, vascular or combined, such as senile dementia of Alzheimer's type (SDAT) or vascular dementia (VaD) and in acute cerebrovascular diseases, such as transient ischemic attack (TIA) and stroke.
The clinical results obtained with alphoscerate choline were higher or equivalent to those observed in the control groups under active treatment and higher than the results observed in the placebo groups. The therapeutic utility of choline alphoscerate for relieving the cognitive symptoms of chronic brain deterioration differentiates this drug from cholinergic precursors used in the past, such as choline and lecithin.